Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-439-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
OptionableNot Optionable
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions
What is Kiniksa Pharmaceuticals' stock symbol?
Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."
How were Kiniksa Pharmaceuticals' earnings last quarter?
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) posted its quarterly earnings results on Thursday, November, 1st. The company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.
When is Kiniksa Pharmaceuticals' next earnings date?
What price target have analysts set for KNSA?
4 Wall Street analysts have issued 1-year price objectives for Kiniksa Pharmaceuticals' shares. Their predictions range from $29.00 to $44.00. On average, they anticipate Kiniksa Pharmaceuticals' stock price to reach $35.3333 in the next year. This suggests a possible upside of 47.4% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.
What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.
Has Kiniksa Pharmaceuticals been receiving favorable news coverage?
Media stories about KNSA stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Kiniksa Pharmaceuticals' key competitors?
Some companies that are related to Kiniksa Pharmaceuticals include FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE).
Who are Kiniksa Pharmaceuticals' key executives?
Kiniksa Pharmaceuticals' management team includes the folowing people:
- Mr. Sanj K. Patel, CEO & Chairman (Age 48)
- Mr. Stephen Mahoney, Pres & COO (Age 47)
- Dr. John F. Paolini, Chief Medical Officer (Age 53)
- Mr. Chris Heberlig, Chief Financial Officer (Age 43)
- Mr. Thomas W. Beetham, Chief Legal Officer (Age 48)
When did Kiniksa Pharmaceuticals IPO?
(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Kiniksa Pharmaceuticals?
Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kiniksa Pharmaceuticals' stock price today?
One share of KNSA stock can currently be purchased for approximately $23.97.
How big of a company is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals has a market capitalization of $1.19 billion. Kiniksa Pharmaceuticals employs 47 workers across the globe.
What is Kiniksa Pharmaceuticals' official website?
How can I contact Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]
MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
